Arrowstreet Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arrowstreet Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,445	Closed	-$2.21M	–	1478
2023 Q2	$2.21M	Buy	21,445 +1,723	+9%	+$182K	﹤0.01%	799
2023 Q1	$2.15M	Sell	19,722 -21,558	-52%	-$2.38M	﹤0.01%	888
2022 Q4	$4.7M	Buy	+41,280	New	+$3.43M	0.01%	693
2022 Q3	–	Sell	-911,752	Closed	-$72.7M	–	1530
2022 Q2	$72.7M	Buy	911,752 +97,141	+12%	+$9.2M	0.1%	177
2022 Q1	$85.7M	Buy	814,611 +476,600	+141%	+$46.4M	0.11%	186
2021 Q4	$36.4M	Buy	+338,011	New	+$36.9M	0.04%	344
2021 Q3	–	Sell	-48,011	Closed	-$4.5M	–	2030
2021 Q2	$4.5M	Buy	+48,011	New	+$4.42M	0.01%	1105
2020 Q3	–	Sell	-8,700	Closed	-$484K	–	2656
2020 Q2	$484K	Buy	+8,700	New	+$372K	﹤0.01%	1975
2019 Q3	–	Sell	-395,041	Closed	-$9.51M	–	1830
2019 Q2	$9.51M	Sell	395,041 -18,175	-4%	-$461K	0.02%	496
2019 Q1	$10.9M	Buy	+413,216	New	+$9.79M	0.03%	538
2015 Q1	–	Sell	-38,506	Closed	-$496K	–	1317
2014 Q4	$496K	Buy	+38,506	New	+$482K	﹤0.01%	1043

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arrowstreet Capital's HZNP Position: Q3 2023 in Review

Arrowstreet Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 21,445 shares — an estimated $2.21M sold.

Arrowstreet Capital first reported a position in HZNP in Q4 2014 and held it in 11 quarters. The position peaked at $85.7M in Q1 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Arrowstreet Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Arrowstreet Capital sold 21,445 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $2.21M.
Arrowstreet Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 11 quarters.
Arrowstreet Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $85.7M in Q1 2022.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Arrowstreet Capital's 13F filing for Q3 2023, filed 14 Nov 2023.